Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma among 4 stocks to hit 52-week highs & rally up to 25% in a month
The Sensex ended higher as select BSE 200 stocks touched fresh 52-week highs. FSN E-Commerce Ventures, Titan, Sun Pharmaceutical Industries and Lenskart Solutions led the momentum.
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
Five Stocks To Buy: Adani Power, Ola Electric, IRCTC And More | June 24, 2026
Top picks for Wednesday, June 24 include Adani Power, Sun Pharmaceutical Industries, Ola Electric, IRCTC, and GRP Limited.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Selling at higher levels turns 23,800 into key barrier for Nifty: Analysts
Benchmark Nifty closed lower last week. Analysts anticipate continued range-bound trading for Nifty this week. Trading strategies suggest buying on dips and selling on rallies within the 23,800-23,200 range. Specific stock recommendations include Indus Towers, Samvardhana Motherson International, Aditya Birla Capital, Sun Pharmaceutical Industries, and Arvind Limited. Investors are advised to consider these opportunities.
Sun Pharma explores funding mix for $12 billion Organon deal
Global lenders are exploring various financing options for Sun Pharmaceutical Industries' proposed $12 billion acquisition of Organon & Co. The Indian drugmaker is considering swapping Organon bondholders into Sun Pharma debt and a potential euro-denominated bond. Additionally, Sun Pharma plans to raise $3 billion to $4 billion in offshore loans, with deal approvals anticipated by December.
Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?
Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & Co. Investors remain cautious as the pharma major nears its biggest-ever overseas acquisition amid debt concerns and volatile global conditions.
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunity
Saion Mukherjee, Managing Director & Head of Equity Research at Nomura says Indian pharmaceutical companies are preparing to tap the opportunity as semaglutide goes off patent. While several large firms such as Sun Pharma, Lupin and Zydus could benefit from the growing diabetes and obesity drug market, Mukherjee highlighted Dr Reddy’s as his top pick in the sector. He said the opportunity will play out across domestic and global markets, with semaglutide likely to become an important growth driver for Indian pharma companies in the coming years.